ASCO 2024 Palbociclib, Pembrolizumab & Endocrine Therapy: Outcomes & Gut Microbiome in HR+/HER2- MBC

For More Videos Like this Subscribe to OncologyTube eNewsletter: https://share.hsforms.com/1dpwSptdCQP...

Dr. Alexis LeVee from City of Hope presents innovative findings from a Phase 1b clinical trial combining CDK4/6 inhibitors with PD-1 inhibitors for hormone receptor-positive, HER2-negative metastatic breast cancer. This study explores the potential of palbociclib, pembrolizumab, and endocrine therapy to enhance anti-tumor responses and improve clinical outcomes.

More Details and Link to Abstract Here:

More Details Here:

🔬 Study Highlights:
Objective: Assess the combined effect of palbociclib (CDK4/6 inhibitor) and pembrolizumab (PD-1 inhibitor) with endocrine therapy.

Cohorts:
Cohort 1: Addition of pembrolizumab in patients with stable disease.
Cohort 2: All three agents administered together from cycle one, day one.
Cohort 3: Pembrolizumab on day one, palbociclib lead-in on day minus one, with endocrine therapy.

Results: Identification of gut bacteria linked to better responses, including Lachnospira, Fecalibacterium, and Allostipes.
Safety: Grade 3/4 adverse events included neutropenia, leukopenia, and liver toxicity, managed with dose adjustments and steroids.
Watch the video to delve into the study's promising results and implications for future breast cancer therapies.

#ASCO2024 #BreastCancer #CancerResearch #Immunotherapy #CityOfHope #Oncology #CDK46Inhibitors #PD1Inhibitors #DrAlexisLeVee